Get started
Author

Dirk Zboralski

Observed names: D Zboralski, D. Zboralski
ORCID: 0000-0002-2224-2452
Observed ORCID: 0000-0002-2224-2452
OpenAlex ID: A5067087141
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177 Lu-FAP-2286: First-in-Humans Results
2021 · Richard P. Baum, Christiane Schuchardt, et al. · Journal of Nuclear Medicine · 386
PDF
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
2022 · Dirk Zboralski, Aileen Hoehne, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 305
PDF
The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization
2013 · Julia Hoellenriegel, Dirk Zboralski, et al. · Blood · 252
Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade
2017 · Dirk Zboralski, Kai Hoehlig, et al. · Cancer Immunology Research · 172
The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys
2013 · Frank Schwoebel, Lucas T. van Eijk, et al. · Blood · 161
SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy
2014 · Aldo M. Roccaro, Antonio Sacco, et al. · Cell Reports · 145
PDF
Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats
2013 · Shie-Chau Liu, Reem Alomran, et al. · Neuro-Oncology · 98
PDF
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
2017 · H Ludwig, K Weisel, et al. · Leukemia · 81
PDF
Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition
2023 · Dirk Zboralski, Frank Osterkamp, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 62
PDF
Preclinical Characterization of DPI-4452: A68Ga/177Lu Theranostic Ligand for Carbonic Anhydrase IX
2024 · Frédéric Massière, Norbert Wiedemann, et al. · Journal of Nuclear Medicine · 54
PDF
Basement membrane component laminin-5 is a target of the tumor suppressor Smad4
2006 · M Zapatka, D Zboralski, et al. · Oncogene · 39
Identification and characterization of a mirror-image oligonucleotide that binds and neutralizes sphingosine 1-phosphate, a central mediator of angiogenesis
2014 · Werner G. Purschke, Kai Hoehlig, et al. · Biochemical Journal · 27
PDF
571P Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP)
2020 · D. Zboralski, F. Osterkamp, et al. · Annals of Oncology · 20
PDF
Divergent mechanisms underlie Smad4-mediated positive regulation of the three genes encoding the basement membrane component laminin-332 (laminin-5)
2008 · Dirk Zboralski, Miriam Böckmann, et al. · BMC Cancer · 17
PDF
Uncoupled responses of Smad4-deficient cancer cells to TNFα result in secretion of monomeric laminin-γ2
2010 · Dirk Zboralski, Bettina Warscheid, et al. · Molecular Cancer · 15
PDF
Preclinical Development of 3BP-3940, a Fibroblast Activation ProteinTargeted Cyclic PeptideBased Radiotheranostic for Imaging and Therapy
2026 · Dirk Zboralski, Frank Osterkamp, et al. · Journal of Nuclear Medicine · 7
Abstract LBA032: Pan-cancer analysis of fibroblast activation protein alpha (FAP) expression to guide tumor selection for the peptide-targeted radionuclide therapy FAP-2286
2021 · Tanya T. Kwan, Minh Nguyen, et al. · Molecular Cancer Therapeutics · 5
Generation and Harnessing of Heterotypic Tumor-Stroma Spheroids to Study Cancer Immunosurveillance
2018 · Dirk Zboralski, Anna Frömming · Methods in molecular biology · 5
Abstract 3317: Comparative biodistribution and radiotherapeutic efficacy of the fibroblast activation protein (FAP)-targeting agents FAP-2286 and FAPI-46
2022 · Dirk Zboralski, Aileen Hoehne, et al. · Cancer Research · 4
Peptide-Targeted Radionuclide Therapy (PTRT) using Lu-177 FAP-2286 in Diverse Adenocarcinomas: Feasibility, Biodistribution and Preliminary Dosimetry in a First-in-human study
2020 · Richard P. Baum, Maythinee Chantadisai, et al. · Journal of Nuclear Medicine · 4
Mode of Action of the SDF-1/CXCL12 Inhibiting Spiegelmer® Nox-A12 and Its Impact On Chronic Lymphocytic Leukemia (CLL) Cell Motility and Chemosensitization
2012 · Dirk Zboralski, Julia Hoellenriegel, et al. · Blood · 4
CXCL12 Inhibition By Nox-A12 (Olaptesed Pegol) Synergizes with the ADCC Activity of CD20 Antibodies By Increasing NK Cell Infiltration in a 3D Lymphoma Model
2016 · Dirk Zboralski, Anna Kruschinski, et al. · Blood · 3
In Vivo Targeting of Stromal-Derived Factor-1 As a Strategy to Prevent Myeloma Cell Dissemination to Distant Bone Marrow Niches
2012 · Aldo M. Roccaro, Antonio Sacco, et al. · Blood · 3
The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration,
2011 · Julia Hoellenriegel, Dirk Zboralski, et al. · Blood · 3
CXCL12 inhibition with NOX-A12 (olaptesed pegol) increases T and NK cell infiltration and synergizes with immune checkpoint blockade in tumour-stroma spheroids
2016 · D. Zboralski, A. Kruschinski, et al. · Annals of Oncology · 2
Works count: 29
Citation count: 1,876
H-index: 15
I10-index: 15
Year
Topic
Type